| 30 |
X |
|
|
2017 |
Thromb Res 153,p76-82(2017) |
Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
|
V Taune
|
| 26 |
X |
X |
|
2016 |
J Clin Med Res 8(12),p899-907(2016) |
Evaluation of the antithrombotic effects of Rivaroxaban and Apixaban using the Total Thrombus-formation Analysis System : in vitro and ex vivo studies
|
H Sugihara
|
| 24 |
X |
X |
|
2016 |
Thromb Haemost 117(01),p75-85(2017) |
Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system
|
A Ågren
|
| 25 |
X |
|
|
2016 |
Thromb Res 146,p69-75(2016) |
Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model
|
K Hosokawa
|
| 23 |
X |
X |
|
2016 |
Heart Vessels 32,p309-316(2017) |
Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System
|
Y Idemoto
|
| 22 |
|
X |
|
2016 |
J Thromb and Haemost 14,p1-10(2016) |
Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy
|
M Yamazaki
|
| 17 |
|
X |
|
2015 |
J Thromb Haemost 13,p1-10(2016) |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy
|
Y Arima
|
| 15 |
X |
X |
|
2015 |
Int J Cardiol 197,p98-100(2015) |
A novel quantitative assessment of whole blood thrombogenicity in patients treated with a non-vitamin K oral anticoagulant
|
D Sueta
|
| 12 |
X |
|
|
2013 |
PLoS One 9(1):e86491 (2014) |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
|
K Hosokawa
|
| 11 |
X |
X |
|
2013 |
J Cardiothorac Vasc Anesth 27(6),e69–e84(2013) |
Influences of Hemodilution and anticoagulation on antiplatelet P2Y12 therapy: in vitro whole blood perfusion model.
|
S Ogawa
|
| 10 |
X |
|
|
2013 |
Thromb Res 133(1),p66-72,(2014) |
Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
|
K Hosokawa
|
| 9 |
X |
|
|
2013 |
Br J Anaesth 111(6),p1013-1023(2013) |
Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions.
|
S Ogawa
|
| 6 |
|
X |
|
2012 |
Thromb Haemost 109(01),p102-111(2013) |
Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
|
K Hosokawa
|
| 3 |
|
X |
|
2011 |
Microvasc Res 83,p154-161(2012) |
A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process.
|
K Hosokawa
|
| 2 |
X |
|
|
2011 |
Thromb Haemost 106(6),p1215-1223(2011) |
A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
|
S Ogawa
|
| 1 |
X |
|
|
2011 |
J Thromb Haemost 9(10),p2029-2037(2011) |
A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions.
|
K Hosokawa
|
